ABBN.SW: $85.88 ▼ -0.22 (-0.26%)ASML.AS: $1,565.20 ▲ 4.40 (0.28%)ENR.DE: $161.54 ▼ -0.96 (-0.59%)GLEN.L: $537.60 ▲ 2.30 (0.43%)IFX.DE: $80.97 ▲ 0.41 (0.51%)NOKIA.HE: $12.16 ▲ 0.16 (1.33%)RIO.L: $7,295.00 ▲ 31.00 (0.43%)AMD: $519.85 ▼ -31.78 (-5.76%)INTC: $132.28 ▼ -8.66 (-6.14%)MU: $1,051.77 ▼ -159.61 (-13.18%)WDC: $670.75 ▼ -61.87 (-8.45%)AAPL: $294.30 ▼ -2.71 (-0.91%)AMZN: $234.11 ▲ 1.32 (0.57%)NVDA: $200.04 ▼ -8.61 (-4.13%)AMAT: $585.88 ▼ -54.30 (-8.48%)CIEN: $459.85 ▼ -0.48 (-0.10%)STX: $1,038.59 ▼ -55.45 (-5.07%)

Company Details

TransMedics Group, Inc.

TMDX - NASDAQ

Identifiants & Marche

Ticker TMDX
ISIN US89377M1099
CIK 0001756262
Bourse NASDAQ
Devise USD

Classification

Secteur Healthcare
Industrie Medical - Devices

Entreprise

Pays US
Siege N/A
Fondee N/A
Site Web Lien

Description

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.